PMID: 9527202Apr 4, 1998Paper

Reduction of allogeneic blood transfusions after open heart operations by lowering cardiopulmonary bypass prime volume

The Annals of Thoracic Surgery
O M ShapiraR J Shemin

Abstract

Despite recent advances in blood conservation techniques, up to 30% to 80% of patients undergoing open heart operations require allogeneic blood transfusions. A prospective, randomized study was performed to test the effect of lowering cardiopulmonary bypass prime volume (as an additional component of an integrated blood conservation strategy) on clinical outcome and allogeneic blood transfusion. One hundred fourteen patients undergoing open heart operations were randomized to either full prime (FP) volume (1,400 mL of Plasmalyte solution) or reduced prime (RP) volume (600 to 800 mL). The reduction of prime volume was achieved by slowly draining the cardiopulmonary bypass circuit into a cell-saving device before the initiation of bypass. Firm transfusion thresholds were observed. There were no significant differences between the groups with respect to baseline characteristics, body surface area, type and urgency of the procedures, perfusion technique, and hematologic profile. Mortality (FP, 1.7%; RP, 0%; p approximately 1.0) and overall morbidity (FP, 28.1%; RP, 22.8%; p = 0.53) were similar. However, transfusion requirements were significantly lower in the RP group: total donor exposure, 3.8 +/- 10.1 versus 1.0 +/- 2.4 units (...Continue Reading

References

Jun 11, 1992·Transfusion·D M SurgenorJ J Collins
Oct 1, 1985·The Annals of Thoracic Surgery·D M CosgroveS B Forsythe
Sep 1, 1995·The Annals of Thoracic Surgery·P G JansenC R Wildevuur
Dec 1, 1996·The Annals of Thoracic Surgery·J F HardyM Samama

❮ Previous
Next ❯

Citations

Jun 25, 2002·The Annals of Thoracic Surgery·Subramaniam BalachandranPeter Hobson
Mar 14, 2013·Interactive Cardiovascular and Thoracic Surgery·Korneel VandewieleKatrien François
Mar 24, 2005·Medical Principles and Practice : International Journal of the Kuwait University, Health Science Centre·Fahad Al-ShammariRiyad Tarazi
Feb 25, 2011·The Heart Surgery Forum·George VretzakisMenelaos Karanikolas
Apr 18, 2006·Journal of Cardiothoracic and Vascular Anesthesia·Glenn S MurphyWilliam J Hoff
Oct 19, 2001·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·P Van der LindenG Simoens
Feb 18, 2016·Journal of Cardiothoracic and Vascular Anesthesia·Tae Sik KimChan-Young Na
Aug 25, 2015·The Annals of Thoracic Surgery·Michelle C EllisUNKNOWN PERForm Registry and the Michigan Society of Thoracic and Cardiovascular Surgeons Quality Collaborative
Oct 29, 2002·The Annals of Thoracic Surgery·Milo C EngorenSamuel J Durham
Jul 22, 2008·The Annals of Thoracic Surgery·Richard W IssittJon R Anderson
Jun 11, 2015·Best Practice & Research. Clinical Anaesthesiology·Florian KraftAlexander Zarbock
Mar 29, 2005·Asian Cardiovascular & Thoracic Annals·Hideaki TakaiKatsuo Nishi
Jul 21, 2009·American Journal of Medical Quality : the Official Journal of the American College of Medical Quality·Franklin W MadduxRobert A Hardin
Feb 14, 2008·Seminars in Cardiothoracic and Vascular Anesthesia·Christine McKay
Sep 22, 2001·Perfusion·M H Cross
Dec 17, 2010·World Journal of Cardiology·Yves Durandy
Nov 29, 2007·ASAIO Journal : a Peer-reviewed Journal of the American Society for Artificial Internal Organs·Yves Durandy
Nov 30, 2006·Journal of Biomedical Materials Research. Part a·Norma Padilla, Arturo Bronson
Jun 14, 2019·ASAIO Journal : a Peer-reviewed Journal of the American Society for Artificial Internal Organs·Alex J ThompsonRonald B Hirschl
Sep 10, 2014·Lab on a Chip·Joseph A Potkay
Dec 17, 2008·Interactive Cardiovascular and Thoracic Surgery·Richard SaczkowskiRamiro Arellano
Aug 22, 2021·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·Saurabh GuptaRichard Whitlock

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.